ImmuneOnco Succesfully Finished First-in-Human Dosing of Its Bi-Specific Fusion Protein IMM2510

       August 18, 2021, Shanghai, China. ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") announced that first-in-human (FIH) dosing of IMM2510, the second product of bi-specific antibodies in clinical stage, has been successfully finished. The phase I clinical study of IMM2510 is being conducted by Fudan University Shanghai Cancer Center. The initial dosing of IMM2510 appeared to be smooth. IMM2510 is a new antibody-receptor recombinant protein (mAb-Trap) that blocks both PD-1/PD-L1 and VEGF/VEGFR signaling pathways, showing great therapeutic potential for a variety of advanced solid tumor indications.

About IMM2510

       IMM2510 is a bi-specific antibody with intellectual property rights, developed based on the unique "mAb-Trap" technical platform of ImmuneOnco. IMM2510 eliminates the immune escape of tumor cells via blocking PD-L1/ PD-1 signaling pathway by targeting PD-L1, and it also activates NK cells and macrophages via Fc-mediated ADCC/ADCP which plays a powerful effect in tumor immunotherapy. At the same time, tumor growth and metastasis were greatly inhibited by blocking VEGF/VEGFR signaling pathway which promotes tumor angiogenesis. Preclinical studies confirmed that IMM2510 achieved significant therapeutic effects in a variety of tumor models. The anti-tumor effect of IMM2510 is superior to the single drug or the combination of two targets with significant advantages of safety. The IMM2510 is designed to use in a variety of indications of advanced solid tumors.

About ImmuneOnco

       Founded in June 2015 at Zhangjiang Hi-Tech Park of China (Shanghai) Pilot Free Trade Zone, ImmuneOnco focuses on development and research of anti-tumor immunotherapy products, including bi-specific antibody-traps (mAb-Traps), novel recombinant proteins, and target-activated NK cell therapy. Our compounds aim to activate patients’ own immune system to exert anti-tumor effects, and ultimately inhibit endless growth of tumor cells and reverse malignant symptoms, so that patients can return gradually to being healthy. Currently, several new anti-tumor products are in clinical development stage. ImmuneOnco is recognized by authorities as one of the ‘Top 50 Start-up Enterprises with the Most Investment Potential in Shanghai’ in 2016, the "Excellent Enterprise" in the 2017 China Innovation and Entrepreneurship Competition, and one of the winners of the "Enterprise Excellence Award" of Shanghai Science and Technology Entrepreneurship in 2017.

For further cooperation, please contact

Address: Room 502, 1043 HaLei Road, Pudong New Area, Shanghai, China

Building 7, Lane 908, Ziping Road, Pudong New Area, Shanghai, China

Tel. + 86 21 5835 6573

website: www.immuneonco.com